CMA
GERM

Cedar Mountain Advisors’s Amplify Treatments, Testing and Advancements ETF GERM Stock Holding History

Cedar Mountain Advisors’s Portfolio GERM Stock Details GERM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-1,116
Closed -$35K – 300
2020
Q4 		$35K Hold
1,116
– – 0.01% 92
2020
Q3 		$31K Buy
+1,116
New +$32.8K 0.01% 86

Other funds holding GERM

Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $71.6B AUM 21.08% 1-Year Est. Return
APA
American Portfolios Advisors Holbrook, New York $2.36B AUM 14.59% 1-Year Est. Return
G
Gainplan Bloomfield Hills, Michigan $254M AUM 25.62% 1-Year Est. Return
CAPTRUST Financial Advisors
CAPTRUST Financial Advisors Raleigh, North Carolina $57.3B AUM 18.32% 1-Year Est. Return
Simplex Trading
Simplex Trading Chicago, Illinois $149B AUM 62.07% 1-Year Est. Return

Cedar Mountain Advisors's GERM Position: Q1 2021 in Review

Cedar Mountain Advisors sold out of Amplify Treatments, Testing and Advancements ETF (GERM) in Q1 2021, closing a stake of 1,116 shares — an estimated $35K sold.

Cedar Mountain Advisors first reported a position in GERM in Q3 2020 and held it in 2 quarters. The position peaked at $35K in Q4 2020. 22 funds tracked by Wall St. Rank hold GERM as of Q1 2021.

  • Cedar Mountain Advisors reported no remaining Amplify Treatments, Testing and Advancements ETF position as of Q1 2021 after selling out during the quarter.
  • Cedar Mountain Advisors sold 1,116 Amplify Treatments, Testing and Advancements ETF shares in Q1 2021, an estimated $35K.
  • Cedar Mountain Advisors first reported a position in Amplify Treatments, Testing and Advancements ETF in Q3 2020 and held it in 2 quarters.
  • Cedar Mountain Advisors's Amplify Treatments, Testing and Advancements ETF position peaked at $35K in Q4 2020.
  • 22 funds tracked by Wall St. Rank held Amplify Treatments, Testing and Advancements ETF as of Q1 2021.

Based on Cedar Mountain Advisors's 13F filing for Q1 2021, filed 23 Apr 2021.